Skystar Bio Pharmaceutical (SKBI) Misses Q4 EPS by 2c; Guides FY11 Revs
Tweet
Share
E-mailGet Alerts SKBI Hot Sheet
Join SI Premium – FREE
Skystar Bio Pharmaceutical Company (Nasdaq: SKBI) reported Q4 EPS of $0.55, $0.02 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $15.8 million versus the consensus estimate of $14.91 million.
Sees FY11 revenue of $60 - $63 million, versus the consensus of $61.16 million.
Sees FY11 revenue of $60 - $63 million, versus the consensus of $61.16 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- KLX Energy narrows Q3 2026 revenue guidance, completes rights offering
- Vail Resorts stock falls 2% on weak pass sales despite Q4 beat
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
